Haemophilus influenzae vaccine

Details Haemophilus influenzae vaccine Haemophilus influenzae vaccine

A - Human Necessities

61

K

167/135

A61K 39/10 (2006.01) A61K 35/74 (2006.01) A61K 39/102 (2006.01) A61K 39/116 (2006.01)

Patent

CA 1117866

ABSTRACT A process for the isolation and purification of immunologically active polyribosyl ribitol phosphate (PRP), the capsular polysaccharide of Haemophilus influenzae type b. The PRP has been purified with ethanol, Cetavlon (hexadecyl- trimethyl ammonium bromide) and a phosphate containing adsor- bent, hydroxylapatite. The contaminants (nucleic acid, pro- teins and endotoxins) are removed to the minimum level by a treatment with hydroxylapatite. Also described is a process for the preparation of a combined vaccine containing the PRP (prepared as forementioned) and B. pertussis antigens. The vaccine elicits anti-PRP antibody and anatipertussis anti- body (as measured by microagglutination) formations in young animals. This sera with anti-PRP antibody exhibits a strong bactericidal activity.

310218

Affiliated with

Also associated with

Rating

Haemophilus influenzae vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Haemophilus influenzae vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Haemophilus influenzae vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-203401